View ValuationGenerate Biomedicines 将来の成長Future 基準チェック /26Generate Biomedicinesの収益は年間9%で減少すると予測されていますが、年間収益は年間33.5%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-55.7% 10.9%なると予測されています。主要情報-9.0%収益成長率10.89%EPS成長率Biotechs 収益成長24.6%収益成長率33.5%将来の株主資本利益率-55.68%アナリストカバレッジGood最終更新日14 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesSeeking Alpha • Jul 23Generate Biomedicines: Post Mega-Money IPO, Caution Is WarrantedSummary Generate Biomedicines is pioneering AI-driven drug discovery, with a $400m IPO and a $1.8bn market cap, targeting asthma, COPD, and oncology. GENB's lead asset, GB-0895, aims for best-in-class, twice-yearly dosing in asthma and COPD, with Phase 3 trials underway and a potential commercial launch by 2028. Strategic partnerships with Amgen and Novartis could yield up to $2.9bn in milestones, but most pipeline assets remain early-stage with limited near-term catalysts. I rate GENB a Hold due to its early development stage, competitive landscape, and lack of imminent value-driving clinical data. Read the full article on Seeking Alphaライブニュース • May 22Nvidia Invests US$10.4 Million in Generate Biomedicines Advancing AI Drug ProgramsNvidia invested US$10.4 million in Generate Biomedicines, providing capital to support the company’s AI-driven generative biology platform. Generate Biomedicines is moving multiple AI-designed drug programs into clinical development, including candidates targeting severe asthma and oncology indications. The Nvidia stake highlights rising interest in AI applications within healthcare and drug discovery, with Generate Biomedicines positioned as an example of this trend. Nvidia’s backing puts a spotlight on Generate Biomedicines’ approach to using AI for drug design and gives the company added financial and reputational support as it advances into clinical testing. Investors may want to track how quickly these programs progress in the clinic and how the company manages the scientific, regulatory and capital risks that come with early-stage drug development.Reported Earnings • May 11First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$1.07 loss per share. Net loss: US$69.2m (flat on 1Q 2025). Revenue exceeded analyst estimates by 70%. Earnings per share (EPS) missed analyst estimates by 105%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.New Risk • May 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$204m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Shares are highly illiquid. Earnings are forecast to decline by an average of 9.0% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years).Recent Insider Transactions • Mar 08CEO & Director recently bought US$240k worth of stockOn the 4th of March, Michael Nally bought around 20k shares on-market at roughly US$12.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.お知らせ • Feb 28Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million.Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $16 Discount Per Security: $1.04 Transaction Features: Reserved Share Offering; Sponsor Backed Offering業績と収益の成長予測NasdaqGS:GENB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202892-331-236N/A412/31/202724-302-223-256612/31/202626-285-239-23363/31/202630-265-234-228N/A12/31/202532-250-204-201N/A12/31/202420-214-121-118N/Aアナリストによる今後の成長予測収入対貯蓄率: GENB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: GENB今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: GENB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: GENBの収益 ( 33.5% ) US市場 ( 12.4% ) よりも速いペースで成長すると予測されています。高い収益成長: GENBの収益 ( 33.5% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GENB 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 12:31終値2026/07/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Generate Biomedicines, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Eric SchmidtCantor Fitzgerald & Co.Salveen RichterGoldman SachsSeamus FernandezGuggenheim Securities, LLC3 その他のアナリストを表示
Seeking Alpha • Jul 23Generate Biomedicines: Post Mega-Money IPO, Caution Is WarrantedSummary Generate Biomedicines is pioneering AI-driven drug discovery, with a $400m IPO and a $1.8bn market cap, targeting asthma, COPD, and oncology. GENB's lead asset, GB-0895, aims for best-in-class, twice-yearly dosing in asthma and COPD, with Phase 3 trials underway and a potential commercial launch by 2028. Strategic partnerships with Amgen and Novartis could yield up to $2.9bn in milestones, but most pipeline assets remain early-stage with limited near-term catalysts. I rate GENB a Hold due to its early development stage, competitive landscape, and lack of imminent value-driving clinical data. Read the full article on Seeking Alpha
ライブニュース • May 22Nvidia Invests US$10.4 Million in Generate Biomedicines Advancing AI Drug ProgramsNvidia invested US$10.4 million in Generate Biomedicines, providing capital to support the company’s AI-driven generative biology platform. Generate Biomedicines is moving multiple AI-designed drug programs into clinical development, including candidates targeting severe asthma and oncology indications. The Nvidia stake highlights rising interest in AI applications within healthcare and drug discovery, with Generate Biomedicines positioned as an example of this trend. Nvidia’s backing puts a spotlight on Generate Biomedicines’ approach to using AI for drug design and gives the company added financial and reputational support as it advances into clinical testing. Investors may want to track how quickly these programs progress in the clinic and how the company manages the scientific, regulatory and capital risks that come with early-stage drug development.
Reported Earnings • May 11First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$1.07 loss per share. Net loss: US$69.2m (flat on 1Q 2025). Revenue exceeded analyst estimates by 70%. Earnings per share (EPS) missed analyst estimates by 105%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
New Risk • May 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$204m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Shares are highly illiquid. Earnings are forecast to decline by an average of 9.0% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years).
Recent Insider Transactions • Mar 08CEO & Director recently bought US$240k worth of stockOn the 4th of March, Michael Nally bought around 20k shares on-market at roughly US$12.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
お知らせ • Feb 28Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million.Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $16 Discount Per Security: $1.04 Transaction Features: Reserved Share Offering; Sponsor Backed Offering